Revolution Medicines Reports Quarterly Results for Q2 2026

What Happened
Revolution Medicines, Inc. announced its financial results for the quarter ended June 30, 2026 in a press release dated August 5, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8-K; the Form 8-K states this information is being furnished (not “filed”) under the Exchange Act. The report was signed by President and CEO Mark A. Goldsmith, M.D., Ph.D.

Key Details

• Date of disclosure: August 5, 2026.
• Reporting period: quarter ended June 30, 2026.
• Press release containing the results is furnished as Exhibit 99.1 to the Form 8-K.
• The Form 8-K clarifies the furnished material is not “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings absent express reference.
• Interactive XBRL cover page (Exhibit 104) is included.

Why It Matters
This 8-K signals that Revolution Medicines has released its latest quarterly results (earnings, revenue, and other financial metrics) to the public; investors should review the attached press release for the specific numbers, operational updates, and any commentary on outlook or cash runway. Note the company furnished — rather than filed — the release, which affects legal incorporation and liability under securities laws.